公开(公告)号：US12065664B2

公开(公告)日：2024-08-20

申请号：US17128736

申请日：2020-12-21

Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.

Inventor： Dan Peer ,  Shiri Weinstein ,  Itai Antoine Toker ,  Srinivas Ramishetti

IPC: A61K39/395 ,  A61K9/00 ,  A61K9/51 ,  A61K31/105 ,  A61K31/7105 ,  A61K31/713 ,  A61K47/68 ,  A61K47/69 ,  A61K48/00 ,  A61P35/02 ,  C07K16/28 ,  C12N15/88

CPC classification number: C12N15/88 ,  A61K9/0019 ,  A61K9/513 ,  A61K31/105 ,  A61K31/7105 ,  A61K31/713 ,  A61K39/395 ,  A61K47/6849 ,  A61K47/6911 ,  A61K48/0066 ,  A61P35/02 ,  C07K16/2812 ,  C07K16/2896

Abstract: Disclosed are targeted lipid based particles for delivery of nucleic acid molecules (such as siRNA) to leukocytes (such as T-Cells and B-cells). Further disclosed are uses of the targeted lipid based particles for treating Leukocytes-associated diseases, such as, cancer.

公开(公告)号：US20240269318A1

公开(公告)日：2024-08-15

申请号：US18626620

申请日：2024-04-04

Applicant: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED

Inventor： Avi SCHROEDER ,  Mor SELA

IPC: A61K47/69 ,  A61P25/16 ,  B82Y5/00

CPC classification number: A61K47/6911 ,  A61P25/16 ,  B82Y5/00

Abstract: In one aspect of the invention, there is provided a nanoparticle comprising a core and a shell, wherein the core comprises a bioactive compound, and the shell comprises a lipid layer comprising a first modified lipid and a additional lipid, wherein the first modified lipid is bound to a targeted moiety via a spacer, and wherein the additional lipid comprises a polymer-bound lipid. The present invention further provides pharmaceutical compositions and methods for therapeutic and/or diagnostic use.

公开(公告)号：US20240216528A1

公开(公告)日：2024-07-04

申请号：US18563311

申请日：2022-05-20

Applicant: Highfield Biopharmaceuticals Corporation

Inventor： Yuhong Xu ,  Xiaolong Chen ,  Shanshan Jin

IPC: A61K47/69 ,  A61K9/127 ,  A61K31/337 ,  A61K31/4745 ,  A61K31/704 ,  A61K33/243 ,  A61K47/24 ,  A61K47/64 ,  A61K47/68

CPC classification number: A61K47/6911 ,  A61K9/127 ,  A61K31/337 ,  A61K31/4745 ,  A61K31/704 ,  A61K33/243 ,  A61K47/24 ,  A61K47/64 ,  A61K47/68

Abstract: An antitumor chemotherapeutic drug liposome having a low drug-to-lipid ratio and an application thereof. The antitumor chemotherapeutic drug liposome comprises an antitumor drug and a liposome as a carrier, wherein the drug-to-lipid ratio of the antitumor drug to the lipid carrier is between 0.01 and 0.15.

公开(公告)号：US20240166498A1

公开(公告)日：2024-05-23

申请号：US17982383

申请日：2022-11-07

Applicant: Academia Sinica

Inventor： Hsiao-hua YU ,  Hsien-Ming LEE ,  Bhaskarchand Sureshchand Gautam

IPC: B81C1/00 ,  A61K47/69 ,  B82Y40/00

CPC classification number: B81C1/00111 ,  A61K47/6911 ,  B82Y40/00 ,  B81B2203/0361

Abstract: Disclosed is a responsive platform, which includes a polymer-grafted nanopillar array, cargo-containing entities, first conjugatable moieties, and second conjugatable moieties. The polymer-grafted nanopillar array includes thermoresponsive polymer brushes grafted onto surfaces of nanopillars, and the cargo-containing entities are attached to the thermoresponsive polymer brushes through non-covalent association between the first conjugatable moieties and the second conjugatable moieties. Accordingly, the cargo-containing entities can be released from the nanopillar array for cellular uptake in a controlled manner by applying thermal stimulus.

公开(公告)号：US11964026B2

公开(公告)日：2024-04-23

申请号：US17892496

申请日：2022-08-22

Applicant: Massachusetts Institute of Technology

Inventor： Antonio Eric Barberio ,  Santiago Correa Echavarria ,  Mariane Bandeira Melo ,  Talar Tokatlian ,  Erik Christopher Dreaden ,  Paula T. Hammond ,  Darrell J. Irvine

IPC: A61K47/54 ,  A61K9/00 ,  A61K9/127 ,  A61K38/20 ,  A61K47/69 ,  A61P35/00

CPC classification number: A61K47/6911 ,  A61K9/0019 ,  A61K9/1271 ,  A61K38/208 ,  A61K47/544 ,  A61P35/00

Abstract: Disclosed are particles for delivering cytokinese, such as IL-12, for the treatment of cancer. The particles comprise cytokines non-covalently bound to liposomes, where the liposomes are coated with polyelectrolytes.

公开(公告)号：US20240124388A1

公开(公告)日：2024-04-18

申请号：US18467190

申请日：2023-09-14

Applicant: ModernaTX, Inc.

Inventor： Kerry E. BENENATO ,  Mark CORNEBISE

IPC: C07C229/12 ,  A61K9/00 ,  A61K9/127 ,  A61K9/16 ,  A61K9/51 ,  A61K31/7105 ,  A61K38/17 ,  A61K38/18 ,  A61K47/54 ,  A61K47/69 ,  A61K48/00 ,  C07C227/16 ,  C07C227/18 ,  C07C229/16 ,  C07C233/36 ,  C07C233/72 ,  C07C235/10 ,  C07C255/24 ,  C07C263/20 ,  C07C271/20 ,  C07C275/14 ,  C07C279/12 ,  C07C279/24 ,  C07C279/28 ,  C07C279/32 ,  C07C311/05 ,  C07C335/08 ,  C07D207/27 ,  C07D233/72 ,  C07D249/04 ,  C07D263/20 ,  C07D265/33 ,  C07D271/06 ,  C07D271/10 ,  C07D277/38 ,  C07F9/09 ,  C07K14/505

CPC classification number: C07C229/12 ,  A61K9/0019 ,  A61K9/0043 ,  A61K9/0073 ,  A61K9/127 ,  A61K9/1272 ,  A61K9/1617 ,  A61K9/1641 ,  A61K9/5123 ,  A61K9/5146 ,  A61K31/7105 ,  A61K38/1725 ,  A61K38/1816 ,  A61K47/543 ,  A61K47/6911 ,  A61K48/0033 ,  A61K48/005 ,  C07C227/16 ,  C07C227/18 ,  C07C229/16 ,  C07C233/36 ,  C07C233/72 ,  C07C235/10 ,  C07C255/24 ,  C07C263/20 ,  C07C271/20 ,  C07C275/14 ,  C07C279/12 ,  C07C279/24 ,  C07C279/28 ,  C07C279/32 ,  C07C311/05 ,  C07C335/08 ,  C07D207/27 ,  C07D233/72 ,  C07D249/04 ,  C07D263/20 ,  C07D265/33 ,  C07D271/06 ,  C07D271/10 ,  C07D277/38 ,  C07F9/091 ,  C07K14/505 ,  A61K9/1271 ,  A61K48/00 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/14 ,  C07C2601/18

Abstract: The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

公开(公告)号：US20240115729A1

公开(公告)日：2024-04-11

申请号：US18276111

申请日：2022-02-04

Applicant: University of Virginia Patent Foundation

Inventor： Kimberly A. Kelly, Ph.D. ,  Jessica Hung

IPC: A61K47/69 ,  A61K31/352 ,  A61K45/06 ,  A61K47/58 ,  A61P5/00 ,  C07K7/06

CPC classification number: A61K47/6911 ,  A61K31/352 ,  A61K45/06 ,  A61K47/605 ,  A61P5/00 ,  C07K7/06

Abstract: Provided are compositions that include targeting peptides and methods for using the same to treat and/or prevent various diseases, disorders, and/or conditions. In some embodiments, the compositions and methods relate to liposomal compositions that include a liposome, the surface of which is conjugated to a peptide having an amino acid sequence as set forth in any of SEQ ID NOS: 3-38, optionally wherein the liposome encapsulates a therapeutic agent or a detectable agent. In some embodiments, the peptide has an amino acid sequence that is one of SEQ ID NOs: 14, 19, 20, 27, and 28. Also provided are methods treating or preventing fibrosis, for decreasing the incidence of a disease, disorder, or condition associated with chronic pancreatitis (CP), for targeting active agents to targets, including but not limited to collagen III-expressing cells and extracellular matrix, and for decreasing incidence of side effects associated with apigenin treatment.

公开(公告)号：US11944706B2

公开(公告)日：2024-04-02

申请号：US17942617

申请日：2022-09-12

Applicant: ANJARIUM BIOSCIENCES AG

Inventor： Joel de Beer

IPC: A61K9/127 ,  A61K47/69 ,  C07K16/28 ,  C12N15/113 ,  C12N15/88

CPC classification number: A61K9/1272 ,  A61K9/1271 ,  A61K9/1277 ,  A61K47/6911 ,  A61K47/6913 ,  C07K16/2896 ,  C12N15/113 ,  C12N15/88 ,  C07K2317/54 ,  C07K2317/55 ,  C12N2310/14 ,  C12N2310/531 ,  Y02A50/30

Abstract: The present invention provides a hybrid biocompatible carrier (hybridosome) which comprises structural and bioactive elements originating from at least one biocompatible delivery module (BDM) and at least one engineered drug encapsulation module (EDEM) comprising at least one tunable fusogenic moiety. The invention further provides pharmaceutical compositions comprising said hybridosomes, processes for their manufacture, as well as pharmaceutical uses and pharmaceutical methods based thereon.

公开(公告)号：US20240082407A1

公开(公告)日：2024-03-14

申请号：US18445174

申请日：2023-05-08

Applicant: Nammi Therapeutics, Inc.

Inventor： Tahmineh Safaie

IPC: A61K47/54 ,  A61K47/69 ,  A61P35/00

CPC classification number: A61K47/554 ,  A61K47/548 ,  A61K47/549 ,  A61K47/6911 ,  A61K47/6929 ,  A61P35/00

Abstract: Formulated and/or co-formulated nanocarriers (e.g., LNPs and/or SLNPs) comprising PD-1 Prodrugs and methods of making the nanocarriers are disclosed herein. The PD-1 Prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit PD-1-L1/L2. The PD-1 Prodrugs can be formulated and/or co-formulated into a nanocarrier to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.

公开(公告)号：US20240050523A1

公开(公告)日：2024-02-15

申请号：US18447152

申请日：2023-08-09

Applicant: SHIFTBIO INC. ,  KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Gi-Hoon NAM ,  Gi Beom KIM ,  Jae Hyun KIM ,  Yeji LEE ,  Jiyoung GOO ,  Seongeun CHO ,  Cherlhyun JEONG ,  In-San KIM

IPC: A61K38/17 ,  A61K9/127 ,  A61K47/65 ,  A61P1/16 ,  A61P29/00 ,  A61K47/69 ,  A61K47/64

CPC classification number: A61K38/1709 ,  A61K9/127 ,  A61K38/177 ,  A61K47/65 ,  A61P1/16 ,  A61P29/00 ,  A61K47/6911 ,  A61K47/64

Abstract: The present invention generally relates to an extracellular vesicle (EV) comprising a subunit of a heterodimeric transcription factor, an EV polypeptide, and a monomeric cis-cleaving intein and a method of using the EV.